ABCC2 and hepatocellular carcinoma: However, some TKIs such as sorafenib plays a dual role in multidrug resistance as it down-regulates ABCB1 and ABCC2 in HCC, hence opening new therapeutic options for TKI in the treatment of HCC (81).